From peptides to peptidomimetics: Design of nonpeptide ligands for major histocompatibility proteins

Pharmaceutica Acta Helvetiae

Volumn 73, Issue 4, 1998, Pages 173-181

  Krebs, Stefan ^a,b   Rognan, Didier ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

MHC; Peptidomimetic; Structure based design

Indexed keywords

LIGAND; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG MECHANISM; IMMUNOMODULATION; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; VACCINATION;

EID: 0032402418     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(98)00021-1     Document Type: Article

References (53)

1. Adams S., Humphreys R.E. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur. J. Immunol. 25:1995;1693-1702.
2. Adams S., Albericio F., Alsina J., Smith E.R., Humphreys R.E. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneim.-Forsch./Drug Res. 47:1997;1069-1077.
3. Adorini L., Muller S., Cardinaux F., Lehmann P.V., Falcioni F., Nagy Z.A. In vivo competition between self-peptides and foreign peptides in T-cell activation. Nature. 334:1988;623-625.
4. Alam S.M., Travers P.J., Wung J.L., Nasholds W., Redpath S., Jameson S.C., Gascoigne N.R.J. T-cell receptor affinity and thymocyte positive selection. Nature. 381:1996;616-620.
5. + T cell clone. Eur. J. Immunol. 27:1997;1387-1391.
6. Batalia M.A., Collins E.J. Peptide binding by class I and class II molecules. Biopolymers. 43:1997;281-302.
7. Bouvier M., Wiley D.C. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science. 265:1994;398-402.
8. Bouvier M., Wiley D.C. Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules. Proc. Natl. Acad. Sci. USA. 93:1996;4583-4588.
9. Chen B.P., Parham P. Direct binding of influenza peptides to class I HLA molecules. Nature. 337:1989;743-745.
10. Cunningham B.R., Rivetna M., Tolman R.L., Flattery S.J., Nichols E.A., Schwartz C.D., Wicker L.S., Hermes J.D., Jones A.B. SAR for MHC class II binding tetrapeptides: correlation with potential binding site. Bioorg. Med. Chem. Letters. 7:1997;19-24.
11. Deres K., Schild H., Wiesmuller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564.
12. Ettouati L., Salvi J.P., Trescol-Biemont M.C., Walchshofer D., Gerlier D., Rabourdin-Combe C., Paris J. Substitution of peptide bond 53-54 of HEL (52-61) with an ethylene bond rather than reduced peptide bond is tolerated by an MHC-II restricted T cell. Peptide Res. 9:1996;248-253.
13. Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 384:1996;134-141.
14. Garcia K.C., Degano M., Pease L.R., Huang M., Peterson P.A., Teyton L., Wilson I.A. Structural basis of plasticity in T cell recpeotr recognition of a self peptide-MHC antigen. Science. 279:1998;1666-1672.
15. u. J. Immunol. 148:1992;3049-3054.
16. Guichard G., Benkirane N., Zeder-Lutz G., Van Regenmortel M.H.V., Briand J.P., Muller S. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc. Natl. Acad. Sci. USA. 91:1994;9765-9769.
17. Guichard G., Calbo S., Muller S., Kourilsky P., Briand J.P., Abastado J.P. Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. J. Biol. Chem. 270:1995;26057-26059.
18. Guichard G., Connan F., Graff R., Ostankovitch M., Muller S., Guillet J.G., Choppin J., Briand J.P. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J. Med. Chem. 39:1996;2030-2039.
19. Hammer J., Belunis C., Bolin D., Papadopoulos J., Walsky R., Higelin J., Danho W., Sinigaglia F., Nagy Z.A. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. USA. 91:1994;4456-4460.
20. Hanson G.J., Vuletich J.L., Bedell L.J., Bono C.P., Howard S.C., Welply J.K., Woulfe S.L., Zacheis M.L. Design of class II (DR4) ligands using conformationally restricted amino acids at P3 and P5. Bioorg. Med. Chem. Letters. 6:1996;1931-1936.
21. Hernandez J.F., Cretin F., Lombard-Platet S., Salvi J.P., Walchshofer N., Gerlier D., Paris J., Rabourdin-Combe C. Critical residue combinations dictate peptide presentation by MHC class II molecules. Peptides. 15:1994;583-590.
22. Hervé M., Maillère B., Mourier G., Texier C., Leroy S., Ménez A. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34:1997;157-163.
23. Hill C.M.A., Liu A., Marshall K.W., Mayer J., Jorgensen B., Yuan B., Cubbon R.M., Nichols E.A., Wicker L.S., Rothbard J.B. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J. Immunol. 27:1994;2890-2898.
24. Hurtenbach U., Lier E., Adorini L., Nagy Z.A. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. J. Exp. Med. 177:1993;1499-1504.
25. Ishioka G.Y., Adorini L., Guery J.C., Gaeta F.C.A., LaFond R., Alexander J., Powell M., Sette A., Grey H.M. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. J. Immunol. 152:1994;4311-4319.
26. Jameson S.C., Hogquist K.A., Bevan M.J. Positive selection of thymocytes. Annu. Rev. Immunol. 13:1995;93-126.
27. Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C. Identification of self-peptides bound to purified HLA-B27. Nature. 353:1991;326-329.
28. Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., Wiley D.S. Crystallographic analysis of endogeneous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc. Natl. Acad. Sci. USA. 93:1996;734-738.
29. Krebs, S., Folkers, G., Rognan, D., 1998a. Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705. J. Peptide Sci., in press.
30. Krebs, S., Lamas, J.R., Poenaru, S., Seebach, D., Lopez de Castro, J.A., Folkers, G., Rognan, D., 1998b. Substituting the TcR binding region of HLA-B27 restricted peptides with organic spacers. J. Biol. Chem., in press.
31. López de Castro J.A. The pathogenic role of JLA-B27 in chronic arthritis. Curr. Opin. Immunol. 10:1998;59-66.
32. Madden D.R. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13:1995;587-682.
33. Madden D.R., Gorga J.C., Strominger J.L., Wiley D.C. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature. 353:1991;321-325.
34. Madden D.R., Garboczi D.N., Wiley D.C. The antigenic identity of peptide/MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell. 75:1993;693-708.
35. Melero I., Bach N., Chen L. Costimulation, tolerance and ignorance of cytotytic T lymphocytes in immune responses to tumor antigens. Life Sci. 60:1997;2035-2041.
36. Meziere C., Viguier M., Dumortier H., Lo-Man R., Leclerc C., Guillet J.-G., Briand J.-P., Muller S. In vivo T helper cell response to retro-inverso peptidomimetics. J. Immunol. 159:1997;3230-3237.
37. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S., Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:1996;2539-2548.
38. Raghavan M., Lebron J.A., Johnson J.L., Bjorkman P.A. Extended repertoire of permissible peptide ligands for HLA-B*2702. Protein Science. 5:1996;2080-2088.
39. Rammensee H.-G., Friede T., Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
40. Rognan D., Scapozza L., Folkers G., Daser A. Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T cell epitopes. Biochemistry. 33:1994;11476-11485.
41. Rognan D., Scapozza L., Folkers G., Daser A. Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leucocyte antigen. Proc. Natl. Acad. Sci. 92:1995;753-757.
42. Rognan D., Krebs S., Kuonen O., Lamas J.R., López de Castro J.A., Folkers G. Fine specificity of antigen binding to two class I major histocompatibility proteins (B*2705 and B*2703) differing in a single amino acid residue. J. Comp.-Aided Mol. Des. 11:1997;463-478.
43. Rognan, D., 1998. Molecular modelling of protein-peptide complexes - Application to major histocompatibility proteins. Habilitationsschrift, Eidgenossiche Technische Hochschule (ETH), Zürich.
44. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restito N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. 4:1998;321-327.
45. Rötzschke O., Falk K. Origin, structure and motifs of naturally processed MHC class II ligands. Curr. Opin. Immunol. 6:1994;45-51.
46. Rovero P., Vigano S., Pegorado S., Revoltella R., Riganelli D., Fruci D., Greco G., Butler R.H., Tanigaki N. Augmentation of the affinity of HLA class I-binding peptides lacking primary anchor residues by manipulation of the secondary anchor residues. J. Peptide Sci. 1:1995;266-273.
47. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 74:1993;929-937.
48. Saper M.A., Bjorkman P.J., Wiley D.C. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J. Mol. Biol. 219:1991;277-319.
49. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215-221.
50. Valitutti S., Müller S., Cella M., Padovan E., Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 375:1995;148-151.
51. Weiss G.A., Collins E.J., Garboczi D.N., Wiley D.C., Schreiber S.L. A tricyclic ring system replaces the variable regions of peptides presented by three alleles of human MHC class I molecules. Chemitry and Biology. 2:1995;401-407.
52. Weiss G.A., Valentekovich R.J., Collins E.J., Garboczi D.N., Lane W.S., Schreiber S.L., Wiley D.C. Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. Proc. Natl. Acad. Sci. USA. 93:1996;10945-10948.
53. Woulfe S.L., Bono C.P., Zacheis M.L., Welpy J., Kirschmann D.A., Baudino T.A., Wang Y., Stone D.A., Hanson G.J., Vuletich J.L., Bedell L.J., Schwartz B.D., Howard S.C. A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation. J. Pharmacol. Exp. Ther. 281:1997;663-669.